Advertisement

NLS AlzeCure

Financing - March 25, 2022

Outcome in AlzeCure’s rights issue

AlzeCure Pharma has announced the outcome of the rights issue with preferential rights for the shareholders that ended on March 22, 2022. The subscription breakdown show that approximately 59.4 percent was subscribed with and without the exercise of subscription rights. Consequently underwriters of the Rights Issue will be allocated approximately 20.8 percent of the Rights […]

Uncategorized - October 7, 2021

AlzeCure drug candidate is based on a 2021 Nobel discovery

AlzeCure Pharma is developing a novel clinical drug candidate for peripheral neuropathic pain, which is based on the seminal discoveries of TRPV1 by Professor Julius, and for which he is awarded the Nobel Prize in Medicine 2021. David Julius has together with Ardem Patapoutian recently been awarded the 2021 Nobel Prize in Physiology or Medicine. […]

Clinical Trials - August 30, 2021

AlzeCure receives phase I trial approval

AlzeCure Pharma has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer’s disease. “This is a statement of strength that shows that AlzeCure continues to deliver according to plan,” says Martin Jönsson, CEO of AlzeCure Pharma. […]

Clinical Trials - August 3, 2021

AlzeCure presents new study results

AlzeCure Pharma has presented new study results at at the Alzheimer’s Association International Conference (AAIC) 2021. The new results demonstrate how their clinical candidate drug ACD856 for Alzheimer’s disease binds to neurotrophin receptors, so-called Trk receptors. The studies show that ACD856 affects important neurotransmitters in areas of the brain that play an important role in cognition […]

Clinical Trials - September 24, 2016

Alzecure announces positive data

AlzeCure announced that data from its TrkA and TrkB positive allosteric modulator program for Alzheimer’s disease will be presented at the 17th International Conference on Alzheimer’s Drug Discovery in Jersey City, NJ, USA. The oral presentation will include preclinical in vivo Proof-of-Principle data of AC-1122, an approved drug that is undergoing repurposing for the treatment […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.